Invention Grant
- Patent Title: Inhibitor of inflammasome activation
-
Application No.: US16076092Application Date: 2017-02-08
-
Publication No.: US11376235B2Publication Date: 2022-07-05
- Inventor: Shimpei Watanabe , Ayako Arai , Yuichi Takajo , Satoshi Inamasu , Satoshi Yomoda , Akiko Ohno , Yuko Kitahara , Taisaku Kanatani
- Applicant: KRACIE HOLDINGS, LTD.
- Applicant Address: JP Tokyo
- Assignee: KRACIE HOLDINGS, LTD.
- Current Assignee: KRACIE HOLDINGS, LTD.
- Current Assignee Address: JP Tokyo
- Agency: Greenblum & Bernstein, P.L.C.
- Priority: JPJP2016-021844 20160208
- International Application: PCT/JP2017/004648 WO 20170208
- International Announcement: WO2017/138586 WO 20170817
- Main IPC: A61K36/00
- IPC: A61K36/00 ; A61K31/365 ; A61K31/7048 ; A61K36/28 ; A61K36/634 ; A23L33/105 ; A61Q19/00 ; A61K8/97 ; A61K8/49 ; A61P3/10 ; A61P17/06 ; A61P25/16 ; A61P9/00 ; A61P1/16 ; A61P27/02 ; A61P13/12 ; A61P9/10 ; A61P29/00 ; A61P3/04 ; A61P17/10 ; A61P25/28 ; A61P17/00 ; A61P17/14 ; A61K8/9789 ; A61K8/60
Abstract:
To provide a novel inflammasome inhibitor capable of inhibiting activation of inflammasome, the present inventors newly found that arctigenin reduces the amount of 1L-1β released and the amount of activated caspase-1 upon stimulation with ATP, palmitic acid, MSU and Poly(dA:dT) and thus has an effect of inhibiting inflammasome activation. The present invention provides an inhibitor of inflammasome activation that comprises arctigenin as an active ingredient.
Public/Granted literature
- US20190099400A1 INHIBITOR OF INFLAMMASOME ACTIVATION Public/Granted day:2019-04-04
Information query
